Gregory Beuerlein

Title: Gregory Beuerlein: Innovator in Anti-c-Met Antibodies

Introduction

Gregory Beuerlein is a notable inventor based in Spring Valley, California. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies that target human c-Met. His work is crucial for advancing cancer treatment and diagnostics.

Latest Patents

Gregory Beuerlein holds a patent for "Anti-c-Met antibodies." This invention relates to antibodies or antigen-binding fragments that bind to the extracellular domain of human c-Met. The patent includes compositions and kits comprising such c-Met antibodies, as well as methods for using them to detect human c-Met. This innovation aids in identifying patients with tumors that express or overexpress human Met, thereby improving their treatment response with anti-c-Met therapeutics.

Career Highlights

Gregory Beuerlein is currently employed at Eli Lilly and Company, a leading global pharmaceutical company. His work at Eli Lilly focuses on developing innovative solutions for complex medical challenges. His expertise in antibody technology has positioned him as a key player in the field.

Collaborations

Some of Gregory's coworkers include Julian Davies and Irene Jennifer Denning. Their collaborative efforts contribute to the advancement of research and development in the biotechnology sector.

Conclusion

Gregory Beuerlein's contributions to the field of anti-c-Met antibodies exemplify the impact of innovative thinking in biotechnology. His work not only enhances our understanding of cancer treatment but also paves the way for future advancements in medical science.